Because immune checkpoint blockade therapy can restore (at least partially) the function of exhausted CD8+ T cells in a subset of patients with cancer (Ribas and Wolchok, 2018; Sharma and Allison, 2015), defining the mechanisms that regulate tumor-specific CD8+ T cell tolerance has garnered much attention in the past decade. This evidence concerns the gene CD8A and cancer.